TLX Shares Telix Pharmaceuticals Limited
BUY ASX · ASXCommercial radiopharmaceutical growth and positive analyst coverage support continued pipeline-driven appreciation.
Future value: $24.17 (+88.98%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Analyst buy rating despite recent weakness
- ▾Below 50-day MA (-19.45%)
- ▸~89% upside to price target
Is TLX a buy right now?
Trend: TLX is trading below the 50-day average (-19.08%), RSI 53 — neutral momentum, with a 3-month return of -11.38%.
Valuation & quality: Telix Pharmaceuticals Limited trades on a trailing P/E of 91.8, forward P/E -387.0, price-to-book 6.29; fundamentals show net margin 3.8%, return on equity 7.4%, revenue growth 22.3% year on year.
Analyst consensus: 11 analysts have a mean 12-month price target of A$24.17 (+89% vs the last close; range A$18.80 – A$31.50), consensus rating “buy”.
Our screen: BUY (score 2) — Commercial radiopharmaceutical growth and positive analyst coverage support continued pipeline-driven appreciation.
Computed from end-of-day data; not personal advice.
Our track record with TLX
Our simulated $10,000 funds have traded TLX 1 time — 1 of 1 closed trade profitable.
| Fund | Bought | Sold | Return |
|---|---|---|---|
| ASX High-risk | 2026-10-01 @ $15.61 | 2026-10-08 @ $15.85 · Defensive switch | +1.54% |
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +32.00% | +13.60% | -13.10% | +27.20% | -14.30% | +8.10% | +2.30% | -18.30% |
Fundamentals
Analyst price target
Technical signals
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Sector: Healthcare · Industry: Biotechnology · Australia · 1,120 employees · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.